44 results about "Troponin T" patented technology

Antibodies and methods are described for the detection and quantitation of cardiac specific troponin I in samples. Cardiac-specific troponin isoforms exist in various forms in the blood, including free and complexed forms. By selecting antibodies that are insensitive and / or sensitive to these various forms, the present invention can provide immunoassays that more accurately reflect the clinical state of an individual. These described antibodies and methods can be used for providing indicators of myocardial infarction and other cardiac pathologies.

The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.

The invention discloses a method for detecting human myocardial troponin T through cytometric bead array. The method comprises the following three steps of: activating a bead, coupling a monoclonal antibody and detecting the human myocardial troponin T, specifically, firstly, activating the beads; secondly, preparing the monoclonal antibody of the carboxylation bead coupled mouse anti human myocardial troponin T; thirdly, capturing the human myocardial troponin T in a specimen; and finally, adding multiple antigenic and fluorescein isothiocyanate labeled donkey anti goat intravenous gamma globulin G of goat anti human myocardial troponin T, and detecting the fluorescence intensity of fluorescein isothiocyanate (FITC) on the bead on a flow cytometry to indirectly detect the content of the human myocardial troponin T in the specimen. The monoclonal antibody coupled bead, the polyclonal antibody of the goat anti human myocardial troponin T, and the fluorescein isothiocyanate labeled donkey anti goat intravenous gamma globulin (IgG) can be prepared into a commodity kit, which can detect the human myocardial troponin T at any time. The method is simple and feasible; and by the method, the human myocardial troponin T can be quickly detected with convenience and the basis for disease diagnosis is provided.

The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and / or a natriuretic peptide.

The present invention relates to diagnostic means and methods. Specifically, the present invention encompasses a method of diagnosing the cause of cardiac necrosis in a subject comprising determining the amount of a cardiac troponin and the amount of a BNP-type peptide in a sample from a subject suffering from cardiac necrosis and comparing the amount of the cardiac troponin and the amount of the BNP-type peptide to reference amounts, whereby the cause of the cardiac necrosis is to be diagnosed. The present invention further relates to a method of determining whether a subject suffering from cardiac necrosis is susceptible for a therapy against initial heart failure and to a method for determining whether a subject suffering from cardiac necrosis is susceptible for a therapy against coronary heart disease. Also encompassed are diagnostic uses, devices, and kits.

A method to facilitate recovery troponin I and / or troponin T from a sample comprising addition of troponin C to the sample or to a surface from which the troponin I and / or troponin T are recovered.

The invention discloses a fluorescence immunochromatographic assay and kit for quantitatively detecting cardiac troponin T (cTnT). The fluorescence immunochromatographic assay for quantitatively detecting cTnT realizes fluorescence quantitative detection on the basis of optimizing various constituent parts of test paper by using excellent fluorescence characteristic of quantum dots and combining a bicolor marking technology and an immunochromatographic technology. Compared with the conventional colloidal gold immunochromatographic assay, the fluorescence immunochromatographic assay disclosed by the invention has the advantages of good marking stability, low non-specificity, high sensitivity, wide linear range and quantifying accuracy. The fluorescence immunochromatographic kit disclosed by the invention is used for carrying out quantitative detection on the cTnT and detecting whole blood, blood serum and blood plasma samples and is suitable for different levels of hospitals and particularly good for wide popularization in primary hospitals and clinics.

Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral / anal sphincter muscle.